Treatment of Hymenoptera venom allergy: an update.

PubWeight™: 0.79‹?›

🔗 View Article (PMID 24887986)

Published in Curr Opin Allergy Clin Immunol on August 01, 2014

Authors

Robbie D Pesek1, Richard F Lockey

Author Affiliations

1: aArkansas Children's Hospital, University of Arkansas for Medical Sciences, Little Rock, Arkansas bUSF Morsani College of Medicine and the James A. Haley Veteran's Hospital, Tampa, Florida, USA.

Articles by these authors

(truncated to the top 100)

Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol (2004) 5.80

Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nat Med (2004) 2.06

Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. J Allergy Clin Immunol (2010) 1.67

Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy (2009) 1.65

Anaphylaxis: a review of causes and mechanisms. J Allergy Clin Immunol (2002) 1.62

Efficacy and safety of low-dose fluticasone propionate compared with montelukast for maintenance treatment of persistent asthma. Mayo Clin Proc (2002) 1.56

NLRP3 deletion protects from hyperoxia-induced acute lung injury. Am J Physiol Cell Physiol (2013) 1.46

Sublingual-oral administration of standardized allergenic extracts: phase 1 safety and dosing results. Ann Allergy Asthma Immunol (2008) 1.46

Exotic pet allergy. J Allergy Clin Immunol (2008) 1.41

2012 Update: World Allergy Organization Guidelines for the assessment and management of anaphylaxis. Curr Opin Allergy Clin Immunol (2012) 1.36

Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language. J Allergy Clin Immunol (2013) 1.33

NALP-3 inflammasome silencing attenuates ceramide-induced transepithelial permeability. J Cell Physiol (2012) 1.32

World Allergy Organization Anaphylaxis Guidelines: 2013 update of the evidence base. Int Arch Allergy Immunol (2013) 1.31

Mechanism of cigarette smoke condensate-induced acute inflammatory response in human bronchial epithelial cells. Respir Res (2002) 1.30

Allergic diseases and asthma: a major global health concern. Curr Opin Allergy Clin Immunol (2012) 1.26

ARIA update: I--Systematic review of complementary and alternative medicine for rhinitis and asthma. J Allergy Clin Immunol (2006) 1.26

Mir-206 regulates pulmonary artery smooth muscle cell proliferation and differentiation. PLoS One (2012) 1.25

Diagnosis and Rationale for Action Against Cow's Milk Allergy (DRACMA): a summary report. J Allergy Clin Immunol (2010) 1.24

Natriuretic peptide receptor a as a novel anticancer target. Cancer Res (2008) 1.14

2'-5' Oligoadenylate synthetase plays a critical role in interferon-gamma inhibition of respiratory syncytial virus infection of human epithelial cells. J Biol Chem (2002) 1.09

Epinephrine: the drug of choice for anaphylaxis-a statement of the world allergy organization. World Allergy Organ J (2008) 1.04

Intranasal gene transfer by chitosan-DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection. Hum Gene Ther (2002) 1.04

Sub-lingual immunotherapy: world allergy organization position paper 2009. World Allergy Organ J (2009) 1.03

Multifunctional magnetic nanoparticles for targeted delivery. Nanomedicine (2009) 1.03

Development of hyaluronic acid-Fe2O3 hybrid magnetic nanoparticles for targeted delivery of peptides. Nanomedicine (2007) 1.01

ERK-1/2 activity is required for efficient RSV infection. FEBS Lett (2004) 1.01

Chitosan IFN-gamma-pDNA Nanoparticle (CIN) Therapy for Allergic Asthma. Genet Vaccines Ther (2003) 0.99

Respiratory syncytial virus infection activates STAT signaling in human epithelial cells. Biochem Biophys Res Commun (2003) 0.96

Thiolated chitosan/DNA nanocomplexes exhibit enhanced and sustained gene delivery. Pharm Res (2006) 0.92

Prevention of airway inflammation with topical cream containing imiquimod and small interfering RNA for natriuretic peptide receptor. Genet Vaccines Ther (2008) 0.92

Adenovirus-mediated interferon gamma gene therapy for allergic asthma: involvement of interleukin 12 and STAT4 signaling. Hum Gene Ther (2002) 0.91

Natriuretic peptides and genesis of asthma: an emerging paradigm? J Allergy Clin Immunol (2004) 0.90

Nanoparticle-mediated gene delivery: state of the art. Expert Opin Biol Ther (2004) 0.90

Attenuation of dengue virus infection by adeno-associated virus-mediated siRNA delivery. Genet Vaccines Ther (2004) 0.89

Interleukin-13 signaling and its role in asthma. World Allergy Organ J (2011) 0.88

Combined fluticasone propionate and salmeterol reduces RSV infection more effectively than either of them alone in allergen-sensitized mice. Virol J (2006) 0.88

Respiratory syncytial virus infection in Fischer 344 rats is attenuated by short interfering RNA against the RSV-NS1 gene. Genet Vaccines Ther (2007) 0.88

Primary gastrointestinal lymphangiectasia presenting as cryptococcal meningitis. Ann Allergy Asthma Immunol (2007) 0.88

Asthma and comorbidities. Curr Opin Allergy Clin Immunol (2013) 0.88

Thiolated chitosan nanoparticles enhance anti-inflammatory effects of intranasally delivered theophylline. Respir Res (2006) 0.87

An immunocompromised BALB/c mouse model for respiratory syncytial virus infection. Virol J (2005) 0.86

Prick puncture skin tests and serum specific IgE as predictors of nasal challenge response to dermatophagoides pteronyssinus in older adults. Ann Allergy Asthma Immunol (2008) 0.86

Immunobiology of grass pollen allergens. Curr Allergy Asthma Rep (2005) 0.85

Allergen prick-puncture skin testing in the elderly. Drugs Aging (2003) 0.85

World Allergy Organization guidelines for prevention of allergy and allergic asthma. Int Arch Allergy Immunol (2004) 0.84

Protein kinase C-alpha activity is required for respiratory syncytial virus fusion to human bronchial epithelial cells. J Virol (2004) 0.84

Allergen immunotherapy: a history of the first 100 years. Curr Opin Allergy Clin Immunol (2011) 0.84

Modulation of lung inflammation by vessel dilator in a mouse model of allergic asthma. Respir Res (2009) 0.84

Do hypoallergenic cats and dogs exist? Ann Allergy Asthma Immunol (2012) 0.83

Mechanism of bronchoprotective effects of a novel natriuretic hormone peptide. J Allergy Clin Immunol (2004) 0.83

Adverse effects and fatalities associated with subcutaneous allergen immunotherapy. Clin Allergy Immunol (2008) 0.82

Serum total IgE and specific IgE to Dermatophagoides pteronyssinus, but not eosinophil cationic protein, are more likely to be elevated in elderly asthmatic patients. Allergy Asthma Proc (2004) 0.82

Atrial natriuretic peptide gene transfer by means of intranasal administration attenuates airway reactivity in a mouse model of allergic sensitization. J Allergy Clin Immunol (2002) 0.82

Efficacy and safety of recombinant C1 inhibitor for the treatment of hereditary angioedema attacks: a North American open-label study. Ann Allergy Asthma Immunol (2013) 0.82

Intranasal IL-12 produces discreet pulmonary and systemic effects on allergic inflammation and airway reactivity. Int Immunopharmacol (2003) 0.81

Systemic reactions to subcutaneous allergen immunotherapy and the response to epinephrine. Allergy Asthma Proc (2011) 0.81

Health economics of allergen-specific immunotherapy in the United States. J Allergy Clin Immunol (2011) 0.80

Patient characteristics associated with allergen immunotherapy initiation and adherence. J Allergy Clin Immunol (2010) 0.80

Regulating the Regulators: microRNA and Asthma. World Allergy Organ J (2011) 0.80

Mite and cockroach proteases activate p44/p42 MAP kinases in human lung epithelial cells. Clin Mol Allergy (2003) 0.80

Aspirin-exacerbated asthma. Allergy Asthma Clin Immunol (2008) 0.79

An update on the safety of specific immunotherapy. Curr Opin Allergy Clin Immunol (2008) 0.79

Increasing cost of epinephrine autoinjectors. J Allergy Clin Immunol (2012) 0.79

Temporomandibular dysfunction: an often overlooked cause of chronic headaches. Ann Allergy Asthma Immunol (2007) 0.79

Safety of binodenoson, a selective adenosine A2A receptor agonist vasodilator pharmacological stress agent, in healthy subjects with mild intermittent asthma. Circ Cardiovasc Imaging (2009) 0.79

Oxymetazoline hydrochloride combined with mometasone nasal spray for persistent nasal congestion (pilot study). World Allergy Organ J (2011) 0.78

Immunotherapy for hymenoptera venom hypersensitivity. Clin Allergy Immunol (2008) 0.78

[Immunotherapy in Latin America. From the past to the future]. Rev Alerg Mex (2008) 0.78

The Role of Aging in Idiopathic Pulmonary Fibrosis. Lung (2015) 0.78

Immunotherapy for hymenoptera venom and biting insect hypersensitivity. Clin Allergy Immunol (2004) 0.77

Adverse effects and fatalities associated with subcutaneous allergen immunotherapy. Clin Allergy Immunol (2004) 0.77

Indoor allergen assessments: a call for universal standards. J Allergy Clin Immunol (2006) 0.77

Melaleuca tree and respiratory disease. Ann Allergy Asthma Immunol (2002) 0.77

We call for iCAALL: International Collaboration in Asthma, Allergy and Immunology. J Allergy Clin Immunol (2012) 0.77

Mite allergens. Clin Allergy Immunol (2008) 0.77

Inflammasome Inhibition Suppresses Alveolar Cell Permeability Through Retention of Neuregulin-1 (NRG-1). Cell Physiol Biochem (2015) 0.76

We Call for iCAALL: International Collaboration in Asthma, Allergy and Immunology. World Allergy Organ J (2012) 0.76

The impact of rhinosinusitis on asthma. Curr Allergy Asthma Rep (2003) 0.76

Symptomatic Primary Selective Immunoglobulin M Deficiency with Nonprotective Pneumococcal Titers Responsive to Subcutaneous Immunoglobulin Treatment. Int Arch Allergy Immunol (2016) 0.75

Mite allergens. Clin Allergy Immunol (2004) 0.75

Weed pollen allergens. Clin Allergy Immunol (2008) 0.75

Respiratory syncytial virus: immunopathology and control. Expert Rev Clin Immunol (2006) 0.75

We call for iCAALL: International Collaboration for Asthma, Allergy and Immunology. Ann Allergy Asthma Immunol (2012) 0.75

ROMO1 links oxidative stress to mitochondrial integrity. J Cell Commun Signal (2014) 0.75

Outcomes of allergy to insect stings in children, with and without venom immunotherapy. J Pediatr (2005) 0.75

EZH2, the moderator in the discussion between methyltransferases at histone H3? J Cell Commun Signal (2014) 0.75

The myth of hypoallergenic dogs (and cats). J Allergy Clin Immunol (2012) 0.75

Mass psychogenic illness presenting as acute stridor in an adolescent female cohort. Ann Otol Rhinol Laryngol (2007) 0.75

Oral curcumin supplementation in patients with atopic asthma. Allergy Rhinol (Providence) (2011) 0.75

Respiratory syncytial virus infection: from biology to therapy: a perspective. World Allergy Organ J (2008) 0.75

Management of insect sting hypersensitivity: an update. Allergy Asthma Immunol Res (2013) 0.75

Important Florida botanical aeroallergens. Allergy Asthma Proc (2010) 0.75

The allergy archives: pioneers and milestones. J Allergy Clin Immunol (2006) 0.75

Visceral sensitivity in gastroesophageal reflux. Dig Dis Sci (2002) 0.75

Instructions and consent forms for allergen immunotherapy. Clin Allergy Immunol (2004) 0.75

Allergic and nonallergic reactions to nitroglycerin. Allergy Asthma Proc (2006) 0.75

Debunking myths about "allergy" to radiocontrast media in an academic institution. Postgrad Med (2015) 0.75

Osteoporosis and asthma. Ann Allergy Asthma Immunol (2006) 0.75

History of immunotherapy: the first 100 years. Immunol Allergy Clin North Am (2011) 0.75

Administration and Burden of Subcutaneous Immunotherapy for Allergic Rhinitis in U.S. and Canadian Clinical Practice. J Manag Care Spec Pharm (2015) 0.75